L-Karnitin Depresyon Üzerinde Etkili Midir?

Özet Karnitin hem endojen biyosentez yoluyla vücutta sentezlenmekte hem de günlük diyetle besinlerden alınmaktadır. Karnitin, serbest karnitin ve asilkarnitinler olarak vücutta bulunmaktadır. Karnitin uzun zincirli yağ asitlerinin β-oksidasyonu için mitokondriye taşıyıcı olarak görev yapmaktadır. Karnitin karboksilik asitler ile ester oluşturma yeteneğinden dolayı diğer metabolitlerin taşınmasında da önem taşımaktadır. Ayrıca karnitin nörotransmitterlerin aktivitesini modüle ederek sinir sisteminde önemli rol oynamaktadır. Depresyon yaşam kalitesinin büyük ölçüde azalması, artmış fiziksel komorbiditeler ve artmış mortalite ile ilişkili bir bozukluktur. Depresyonlu bireylerde yağ asitleri ve lipit metabolizması değişikliklerinin oluştuğu bildirilmiştir. Bu nedenle karnitinin, sinir dokularındaki çeşitli nörotrofik faktörlerin, hücre zarlarının, lipid metabolizmasının ve nörotransmitterlerin aktivitesini modüle ettiği düşünüldüğünde, depresyon tedavisinde karnitin takviyesinin antidepresanlara alternatif tedavi edici ajan olarak potansiyel bir rolü olduğu ileri sürülmüştür. Karnitin beyinde yaygın olarak bulunmakta ve kolinerjik reseptörler üzerinde uyarıcı etki göstermektedir. Ayrıca karnitin nöromodülatör etki göstererek dopamin salınımının artmasını ve gama-aminobutirik asidin artmasını sağlamaktadır. Karnitin sinir sisteminde antioksidan ve nörotrofik etki göstermektedir. Hayvan ve insan modelli klinik çalışmalarda depresyon üzerinde karnitinin olumlu etkilerinin olduğu belirlenmiştir. Karnitin takviyesinin antidepresan ve nörotrofik etkilerinden dolayı depresyon tedavisinde etkin rolü olabileceği düşünülmektedir.

___

  • 1. Wang SM, Han C, Lee SJ, Patkar A, Masand PS, Pae CU. A review of current evidence for acetyl-L-carnitine in the treatment of depression. Journal of Psychiatric Research 2014; 53: 30-7.
  • 2. Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosomatic Medicine 2018; 80(2): 154-59.
  • 3. Nasca C, Bigioa B, Leec FS, Younge SP, Kautzg MM, Albrightd A, et al. Acetyl-L-carnitine deficiency in patients with major depressive disorder. PNAS 2018; 115(34): 8627-32.
  • 4. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate Jr CA. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depression. The Journal of clinical psychiatry 2008; 69(6): 946-958.
  • 5. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998; 43(5): 315–19.
  • 6. Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res 2010; 49(1): 61–75.
  • 7. Ferreira GC, McKenna MC. L-Carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017; 42(6): 1661–75.
  • 8. Sergi G, Pizzato S, Piovesan F, Trevisan C, Veronese N, Manzato E. Effects of acetyl-lcarnitine in diabetic neuropathy and other geriatric disorders. Aging Clin Exp Res 2018; 30(2): 133–38.
  • 9. Traina G. The neurobiology of acetyl-L-carnitine. Frontiers in Bioscience (Landmark Ed) 2016; 21: 1314-29.
  • 10. Ando S, Tadenuma T, Tanaka Y, Fukui F, Kobayashi S, Ohashi Y, et al. Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats. J Neurosci Res 2001; 66(2): 266-271.
  • 11. Janiri L, Falcone M, Persico A, E Tempesta. Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neural Transm Gen Sect 1991; 86(2): 135-146.
  • 12. Smeland OB, Meisingset TW, Borges K, Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochemistry international 2012; 61(1): 100-7.
  • 13. Post RM. Myriad of implications of acetyl-L-carnitine deficits in depression. PNAS 2018; 115(34): 8475–77.
  • 14. Peedicayil J. L-Acetylcarnitine as a histone acetylation modulator in psychiatric disorders. Psychopharmacology 2018; 235(11): 3361–62.
  • 15. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(12): 4804-09.
  • 16. Matrisciano F, Caruso A, Orlando R, Marchiafava M, Bruno V, Battaglia G, et al. Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 2008; 55(4): 525-31.
  • 17. Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, et al. Upregulation of mGlu2 receptors via NF-kappaB p65 acetylation is involved in the proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology 2013; 38(11): 2220-30.
  • 18. Sima AAF, Ristic H, Merry A, Kamijo M, Lattimer SA, Stevens MJ, et al. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996; 97(8): 1900–07.
  • 19. Bigini P, Larini S, Pasquali C, Muzio V, Mennini T. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett 2002; 329(3): 334–38.
  • 20. Silva Adaya D, Pérez De La Cruz V, Herrera Mundo MN, Mendoza Macedo K, Villeda Hernández J, Binienda Z, et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l‐carnitine. Journal of neurochemistry 2008; 105(3): 677-89.
  • 21. Karalija A, Novikova LN, Kingham PJ, Wiberg M, Novikov LN. Neuroprotective effects of N-acetyl-cysteine and acetyl-L-carnitine after spinal cord injury in adult rats. PLoS One 2012; 7(7): e41086.
  • 22. Ferrari F, Gorini A, Villa RF. Functional proteomics of synaptic plasma membrane ATP-ases of rat hippocampus: Effect of L-acetylcarnitine and relationships with Dementia and Depression pathophysiology. European Journal of Pharmacology 2015; 756: 67–74.
  • 23. Levine J, Kaplan Z, Pettegrew JW, McClure RJ, Gershon S, Buriakovsky I, et al. Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats. International Journal of Neuropsychopharmacology 2005; 8(1): 65-74.
  • 24. Wang W, Lu Y, Xue Z, Li Z, Wang C, Zhao X, et al. Rapid-acting Antidepressant-like Effects Of Acetyl-l-carnitine Mediated By PI3K/AKT/BDNF/VGF Signaling Pathway In Mice. Neuroscience 2015; 285: 281–91.
  • 25. Mannelli LDC, Vivoli E, Salvicchi A, Schiavone N, Koverech A, Messano M, et al. Antidepressant-like effect of artemin in mice: a mechanism for acetyl-L-carnitine activity on depression. Psychopharmacology 2011; 218(2): 347-56.
  • 26. Tashiro K, Kaida Y, Yamagishi S, Tanaka H, Yokoro M, Yano J, et al. L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis. Letters in Drug Design & Discovery 2017; 14(6): 737-42.
  • 27. Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, et al. Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scandinavian Journal of Gastroenterology 2011; 46(6): 750–59.
  • 28. Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope Jr HG, et al. A Placebo-Controlled Trial of Acetyl-L-Carnitine and α-Lipoic Acid in the Treatment of Bipolar Depression. J Clin Psychopharmacol. 2013; 33(5): 627–35.
  • 29. Fukami K, Yamagishi S, Sakai K, Kaida Y, Minami A, Nakayama Y, et al. Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis. Aging Male, 2014; 17(4): 238–42.
  • 30. Cassol E, Misra V, Morgello S, Kirk GD, Mehta SH, Gabuzda D. Altered monoamine and acylcarnitine metabolites in HIV-positive and HIV-negative subjects with depression. J Acquir Immune Defic Syndr 2015; 69(1): 18–28.
  • 31. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004; 63(4): 641-6.
  • 32. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: A preliminary analysis. Annals of the New York Academy of Sciences 2004; 1033(1): 168-76.
  • 33. Jamilian H, Jamilian M, Samimi M, Afshar Ebrahimi F, Rahimi M, Bahmani F, et al. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecological Endocrinology 2017; 33(6): 442-7.
  • 34. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl- L -carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006; 16(4): 281 -7.
  • 35. Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, et al. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011; 35(4): 953-8.
  • 36. Rezaee H, Khalili H, Hatamkhani S, Dashti-Khavidaki S, Khazaeipour Z. Frequency of depression and its correlation with serum carnitine level in HIV/AIDS patients. Curr HIV Res. 2013; 11(3): 226-30.
Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi-Cover
  • ISSN: 2146-247X
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2010
  • Yayıncı: Zehra ÜSTÜN